The timing of low dose glucocorticoid therapy in treatment of rheumatoid arthritis

被引:3
|
作者
Karatay, S [1 ]
Senel, K [1 ]
Ugur, M [1 ]
Yildirim, K [1 ]
机构
[1] Ataturk Univ, Sch Med, Dept Phys Med & Rehabil, Erzurum, Turkey
关键词
rheumatoid arthritis; treatment; glucocorticoids; timing of administration;
D O I
10.1163/15685690260138910
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to determine the effects of low-dose prednisolone in treatment of rheumatoid arthritis (RA) administered in the morning or at night. Thirty patients with active RA were divided randomly into two groups. For 6 months, prednisolone was administered at 02:00 am or 07:30 am. During the treatment, changes observed each month in clinical and laboratory status of patients in both groups were recorded and results were compared both within and between the groups. Significant improvements were observed in both groups in clinical and laboratory findings compared to values before treatment, beginning from first month to sixth month (p < 0.001). In comparison of results in both groups, no significant difference was obtained from first month to sixth month (p > 0.05). Low-dose prednisolone therapy in treatment of RA significantly suppresses the activity of disease beginning from the first month. This condition is kept until the sixth month. However, administration of the medication given either in the morning or at night does not affect the results of the treatment.
引用
收藏
页码:305 / 312
页数:8
相关论文
共 50 条
  • [31] Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy
    Choi, BR
    Ahn, MJ
    Lee, W
    Kim, TH
    Bae, SC
    Jun, JB
    RHEUMATOLOGY INTERNATIONAL, 2005, 25 (04) : 311 - 313
  • [32] Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review
    Ruyssen-Witrand, Adeline
    Fautrel, Bruno
    Saraux, Alain
    Le Loet, Xavier
    Pham, Thao
    JOINT BONE SPINE, 2011, 78 (01) : 23 - 30
  • [33] Optimal dose of etanercept in the treatment of rheumatoid arthritis
    Curtis, Elizabeth Mary
    Marks, Jonathan Lewis
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2014, 6 : 27 - 38
  • [34] State-of-the-art glucocorticoid-targeted drug therapies for the treatment of rheumatoid arthritis
    Pelechas, Eleftherios
    Drosos, Alexandros A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (06) : 703 - 711
  • [35] Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy
    Byung-Ryul Choi
    Myung-Ju Ahn
    Woong Soo Lee
    Tae-Hwan Kim
    Sang-Cheol Bae
    Jae-Bum Jun
    Rheumatology International, 2005, 25 : 311 - 313
  • [36] Acute myeloid leukemia in the setting of low dose weekly methotrexate therapy for rheumatoid arthritis
    Kolte, B
    Baer, AN
    Sait, SNJ
    O'Loughlin, KL
    Stewart, CC
    Barcos, M
    Wetzler, M
    Baer, MR
    LEUKEMIA & LYMPHOMA, 2001, 42 (03) : 371 - 378
  • [37] Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink
    Abtahi, Shahab
    Driessen, Johanna H. M.
    Burden, Andrea M.
    Souverein, Patrick C.
    van den Bergh, Joop P.
    van Staa, Tjeerd P.
    Boonen, Annelies
    de Vries, Frank
    RHEUMATOLOGY, 2022, 61 (04) : 1448 - 1458
  • [38] Identifying factors hampering physical activity in longstanding rheumatoid arthritis: what is the role of glucocorticoid therapy?
    van der Goes, M. C.
    Hoes, J. N.
    Cramer, M. J.
    van der Veen, M. J.
    van der Werf, J. H.
    Bijlsma, J. W. J.
    Jacobs, J. W. G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : 155 - 161
  • [39] Analyses of similarities and differences in glucocorticoid therapy between rheumatoid arthritis and ankylosing spondylitis - a systematic comparison
    Spies, C. M.
    Burmester, G. -R.
    Buttgereit, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S152 - S158
  • [40] Treatment with low dose methotrexate in rheumatoid arthritis: Risk factors for serious side effects
    Berthelot, JM
    Glemarec, J
    Chiffoleau, A
    Maugars, Y
    Prost, A
    THERAPIE, 1997, 52 (02): : 111 - 116